Abstracts tagged "Lupus nephritis"

Abstract Number: 130 • 2020 Pediatric Rheumatology Symposium
Anti-Ro/SSA Is Associated with Progression to End-Stage Renal Disease in Anti-dsDNA Positive Lupus Nephritis
Matthew Sherman¹, Amali Gunawardana ², Janine Amirault ², Asha Moudgil ³, James Bost ³ and Hemalatha Srinivasalu ¹, ¹Children's National Medical Center, Washington, ²George Washington University, Washington, ³Children's Health Center, Children's National Medical Center, Washington
Background/Purpose: Lupus nephritis (LN) is related to disease severity, morbidity, and mortality in juvenile systemic lupus erythematosus (jSLE). Cluster analysis emerged to identify autoantibody profiles…
Abstract Number: 692 • 2019 ACR/ARP Annual Meeting
Correlation of Urinary Soluble CD163 Levels with Clinicopathological Features in Lupus Nephritis: Its Role as a Potential Biomarker
Shilpa Venkataraman¹, Ankita Singh ², Manjula Murari ³, Vinita Agrawal ², Amita Aggarwal ³ and Rakesh Pandey ⁴, ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Post Graduate institute of medical science, Lucknow, India, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute for Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Lupus nephritis (LN), is seen in 30-50% patients with SLE and 5-10% patients progress to end-stage renal disease. The clinical disease activity indices do…
Abstract Number: 1917 • 2019 ACR/ARP Annual Meeting
Tubulointerstitial Inflammation Predicts Outcomes in Lupus Nephritis
Charles Oshinsky¹, Mariam Siddiqui ², Vladimir Liarski ³, Anthony Chang ³, Marcus Clark ⁴ and Kichul Ko ³, ¹University of Chicago, Department of Internal Medicine, Chicago, ²Northwestern Memorial Hospital, Chicago, ³University of Chicago, Chicago, ⁴University of Chicago, Chicago, IL
Background/Purpose: Lupus nephritis (LuN) causes significant morbidity and mortality, but predicting which patients will progress still remains imprecise. Current classification schema for LuN and its…
Abstract Number: 2894 • 2019 ACR/ARP Annual Meeting
CD6-ALCAM Signaling Is Upregulated in Kidneys with Lupus Nephritis and Is Associated with Disease Activity
Evan Der ¹, Ting Zhang ², Chi Chiu Mok ³, Ramesh Saxena ⁴, Krishna R. Polu ⁵, Chandra Mohan ⁶ and Chaim Putterman⁷, ¹Albert Einstein College of Medicine, New York, ²Biomedical Engineering, University of Houston, Houston, TX, ³Department of Medicine, Tuen Mun Hospital, Hong Kong, China (People's Republic), ⁴University of Texas South Western, Dallas, TX, ⁵Equillium, San Diego, CA, ⁶University of Houston, Houston, ⁷Albert Einstein College of Medicine, New York, NY
Background/Purpose: Lupus nephritis (LN) is a leading cause of morbidity and mortality in Systemic lupus erythematosus (SLE) patients. However, the pathogenesis of renal disease in…
Abstract Number: 859 • 2019 ACR/ARP Annual Meeting
Long-term Outcome of a Randomized Controlled Trial Comparing Tacrolimus with Mycophenolate Mofetil as Induction Therapy of Severe Lupus Nephritis
Chi Chiu Mok¹, Ling Yin Ho ², Shirley Ying ³, Woon Leung Ng ⁴ and Man Chi Leung ⁴, ¹Department of Medicine, Tuen Mun Hospital, Hong Kong, China (People's Republic), ²Tuen Mun Hospital, Hong Kong, Hong Kong, ³Princess Margaret Hospital, Hong Kong, Hong Kong, ⁴United Christian Hospital, Hong Kong, Hong Kong
Background/Purpose: To report the 10-year outcome of patients with lupus nephritis (LN) treated with combined prednisolone with mycophenolate mofetil (MMF) or tacrolimus (TAC) as induction…
Abstract Number: 1918 • 2019 ACR/ARP Annual Meeting
Urine CD163 Significantly Discriminates Active Lupus Nephritis and Strongly Correlates with Proliferative Glomerulonephritis
Ting Zhang¹, Ramesh Saxena ², Chi Chiu Mok ³, Michelle Petri ⁴ and Chandra Mohan ⁵, ¹Biomedical Engineering, University of Houston, Houston, TX, ²UTSW, Dallas, ³Department of Medicine, Tuen Mun Hospital, Hong Kong, China (People's Republic), ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵University of Houston, Houston
Background/Purpose: CD163 is a marker for alternatively activated M2 macrophages, which have been implicated in the pathogenesis of lupus nephritis (LN). The potential of urine…
Abstract Number: 2895 • 2019 ACR/ARP Annual Meeting
Complement Protein CL-K1 at High Concentrations Protects Against the Development of Lupus Nephritis
Anne Troldborg¹, Anne Voss ², Søren Werner Karlsjov Hansen ³, Jens Christian Jensenius ⁴, Kristian Stengaard-Pedersen ⁵ and Steffen Thiel ⁶, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ²Odense University Hospital, Department of Rheumatology, Odense, Denmark, ³University of Southern Denmark, Odense, Denmark, ⁴Aarhus University, department of biomedicine, Aarhus, Denmark, ⁵Department of Rheumatology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus University, Aarhus, Denmark, Aarhus, Denmark, ⁶Department of Biomedicine, Aarhus University, Aarhus, Denmark, Aarhus, Denmark
Background/Purpose: Nephritis is a severe manifestation of systemic lupus erythematosus (SLE) that develops in 30 to 50 percent of the patients. At the time of…
Abstract Number: 880 • 2019 ACR/ARP Annual Meeting
Diseased Lupus Nephritis Kidneys Serve as a Primary Site of Systemic Autoimmune Development
Matthew Woodruff¹, Christopher Tipton ¹, Jennifer Hom ¹ and Iñaki Sanz ¹, ¹Emory University, Atlanta, GA
Background/Purpose: Lupus nephritis (LN) is an autoimmune destruction of the kidney glomeruli and loss of kidney function affecting almost half of lupus patients. Although the…
Abstract Number: 1930 • 2019 ACR/ARP Annual Meeting
Analysis of Lupus Nephritis Gene Expression Reveals Dysregulation of Pathogenic Pathways Activated Within Infiltrating Cells
Adam Labonte¹, Jackson Xu ², Sarah Heuer ², Robert Robl ², Prathyusha Bachali ¹, Michelle Catalina ¹, Peter Lipsky ³ and Amrie Grammer ⁴, ¹AMPEL Biosolutions and the RILITE Research Institute, Charlottesville, VA, ²AMPEL BioSolutions, Charlottesville, VA, ³AMPEL BioSolutions, LLC, Charlottesville, VA, ⁴AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA
Background/Purpose: LN is a serious complication of SLE that affects about 20-40% of all lupus patients and leads to kidney damage, end-stage renal disease, and…
Abstract Number: 2896 • 2019 ACR/ARP Annual Meeting
The Role of Alterations in the Splicing Machinery in the Pathogenesis of Lupus: Does It Impact Lupus Nephritis?
Chary Lopez-Pedrera¹, Alejandro Ibañez-Costa ¹, Mª Ángeles Aguirre-Zamorano ², Laura Pérez-Sanchez ³, Alejandra Patiño-Trives ¹, Maria Luque-Tevar ¹, Maria del Carmen Abalos-Aguilera ¹, Ivan Arias de la Rosa ⁴, Nuria Barbarroja ⁵, Mario Espinosa ⁶, Eduardo Collantes-Estevez ⁴, Justo Castaño ⁷, Raúl Luque ⁷ and Carlos Perez-Sanchez ⁸, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁵University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ⁶UGC de Nefrología. Hospital Universitario Reina Sofía, Cordoba, Spain, ⁷Maimónides Institute for Biomedical Research at Córdoba, Cordoba, Spain, ⁸Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain
Background/Purpose: The aim of this study was to evaluate whether alterations in the splicing machinery of immune cells could influence the development and activity of…
Abstract Number: 882 • 2019 ACR/ARP Annual Meeting
Serum Anti-Vimentin Autoantibodies May Uniquely Predict Response to Therapy in Lupus Nephritis
Andrew Kinloch¹, Matthew Cascino ², Jian Dai ³, Rene Bermea ¹, Kichul Ko ¹, Margaret Vesselits ⁴, Maureen Legendre ⁵, Michael Okoreeh ¹, David Markovitz ⁵, Leonard Dragone ⁶, Michael Townsend ³ and Marcus Clark ¹, ¹University of Chicago, Chicago, IL, ²Genentech, Inc., San Fransisco, CA, ³Genentech, San Fransisco, CA, ⁴University of Chicago, Chicago, ⁵University of Michigan, Ann Arbor, MI, ⁶UCSF, San Fransisco, CA
Background/Purpose: Tubulointerstitial inflammation (TII) in lupus nephritis (LN) is associated with a worse prognosis. Vimentin, a cytoplasmic antigen, is commonly targeted by in situ activated…
Abstract Number: 2046 • 2019 ACR/ARP Annual Meeting
NMR Spectroscopy Reveals Alterations of Urinary Acetate and Citrate Levels Following Cyclophosphamide Therapy in Patients with Lupus Nephritis
Sujata Ganguly¹, Umesh Kumar ², Anupam Guleria ³, Sanjukta Majumder ⁴, Sanat Phatak ¹, Smriti Chaurasia ¹, Nikhil Gupta ⁵, Sandeep Kumar ⁶, Amita Aggarwal ⁷, Dinesh Kumar ³ and Ramnath Misra ⁴, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, India, ²Centre of Biomedical Research SGPGIMS, Raibareli Road, Lucknow-226014, India, Lucknow, Uttar Pradesh, India, ³Centre for Biomedical Research, Sanjay Gandhi Post Graduate Institute of Medical Science, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, ⁵Centre for Biomedical Research, Lucknow, DELHI, Delhi, India, ⁶Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Post Graduate Institute of Medical Science, Lucknow, Uttar Pradesh, India, ⁷Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Metabolomics, the study of global alterations in small metabolites is a useful tool to look for novel biomarkers. Recently, we reported a reprogramming of…
Abstract Number: 2898 • 2019 ACR/ARP Annual Meeting
Evaluation of the Transcriptome of Non-Lesional, Non-Sun Exposed Skin in Patients with Lupus Nephritis
Hemant Suryawanshi¹, Robert Clancy ², Evan Der ³, Peter Izmirly ², H Michael Belmont ⁴, Chaim Putterman ⁵, Jill Buyon ² and Thomas Tuschl ¹, ¹Rockefeller Research Laboratories, New York, ²NYU School of Medicine, New York, ³Albert Einstein College of Medicine, New York, ⁴NYU Langone Health, New York, NY, ⁵Albert Einstein College of Medicine, New York, NY
Background/Purpose: The impact of renal injury in lupus nephritis (LN) is widespread with consequences to resident cells in other tissue beds, even non-lesional, non-sun exposed…
Abstract Number: 941 • 2019 ACR/ARP Annual Meeting
Treatment of Lupus Nephritis with anti-CD20 Followed by Anti-BAFF: Impact on B Cell Reconstitution, B Cell Subsets, and Autoreactivity
Yemil Atisha Fregoso¹, Susan Malkiel ², Kristina Harris ³, Sai Kanaparthi ³, Margie Byron ⁴, Linna Ding ⁵, Dawn Smilek ⁶, David Wofsy ⁷, Maria Dall'Era ⁸, Cynthia Aranow ¹ and Betty Diamond ⁹, ¹Feinstein Institute for Medical Research, Manhasset, NY, ²Feinstein Institute for Medical Research, Manhasset, ³Immune Tolerance Network, Bethesda, ⁴Rho Federal Systems, Inc., Chapel Hill, NC, ⁵National Institute of Allergy and Infectious Diseases, Bethesda, MD, ⁶Immune Tolerance Network, San Francisco, CA, ⁷UCSF, San Francisco, ⁸University of California, San Francisco, San Francisco, CA, ⁹Feinstein Institutes for Medical Research, Manhasset
Background/Purpose: Despite the relevance of B cells in lupus, two clinical trials of anti-CD20 failed to meet primary endpoints in patients with lupus and lupus…
Abstract Number: 2116 • 2019 ACR/ARP Annual Meeting
Serious Infection in Patients with Systemic Lupus Erythematosus, Lupus Nephritis and Rheumatoid Arthritis Compared to the General Population: Incidence Rates Using Real-World Claims Data
Lisa Lindsay¹, Ching-Yi Chuo ², Nicholas Jones ², Joshua Galanter ², Anna McGregor ² and Katie Tuckwell ², ¹Genentech Inc, SOUTH SAN FRANCISCO, CA, ²Genentech Inc, SOUTH SAN FRANCISCO
Background/Purpose: Patients with systemic lupus erythematosus (SLE), lupus nephritis (LN) and rheumatoid arthritis (RA) are at risk of serious infections (SIs) due to the impact…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].